Venus Remedies Limited (VENUSREM.BO)
INR 303.0
(-0.61%)
INR 303.0
(-0.61%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 2.18 Billion INR | -28.46% |
| 2022 | 2.08 Billion INR | 4.59% |
| 2021 | 1.98 Billion INR | 1.38% |
| 2020 | 1.96 Billion INR | 27.01% |
| 2019 | 1.54 Billion INR | 23.57% |
| 2018 | 1.24 Billion INR | -19.63% |
| 2017 | 1.55 Billion INR | -2.69% |
| 2016 | 1.59 Billion INR | -4.96% |
| 2015 | 1.68 Billion INR | -9.78% |
| 2014 | 1.86 Billion INR | -18.38% |
| 2013 | 2.28 Billion INR | 14.9% |
| 2012 | 1.98 Billion INR | 12.29% |
| 2011 | 1.76 Billion INR | 9.51% |
| 2010 | 1.61 Billion INR | 32.37% |
| 2009 | 1.22 Billion INR | 21.47% |
| 2008 | 1 Billion INR | 25.08% |
| 2007 | 803.46 Million INR | 51.01% |
| 2006 | 532.06 Million INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 267.9 Million INR | -45.88% |
| 2024 Q2 | 317.6 Million INR | 18.55% |
| 2023 FY | 1.48 Billion INR | -28.46% |
| 2023 Q1 | 472.1 Million INR | -9.5% |
| 2023 Q3 | 303.4 Million INR | -56.78% |
| 2023 Q4 | 495 Million INR | 63.15% |
| 2023 Q2 | 702 Million INR | 48.7% |
| 2022 Q1 | 569.1 Million INR | 67.72% |
| 2022 Q4 | 521.68 Million INR | 12.02% |
| 2022 FY | 2.08 Billion INR | 4.59% |
| 2022 Q3 | 465.7 Million INR | -11.06% |
| 2022 Q2 | 523.6 Million INR | -8.0% |
| 2021 Q2 | 664.6 Million INR | 31.76% |
| 2021 Q4 | 339.32 Million INR | -31.53% |
| 2021 Q1 | 504.4 Million INR | 100.54% |
| 2021 FY | 1.98 Billion INR | 1.38% |
| 2021 Q3 | 495.6 Million INR | -25.43% |
| 2020 Q3 | 530.86 Million INR | 7.31% |
| 2020 Q2 | 494.69 Million INR | -27.74% |
| 2020 Q4 | 251.52 Million INR | -52.62% |
| 2020 Q1 | 684.57 Million INR | 105.1% |
| 2020 FY | 1.96 Billion INR | 27.01% |
| 2019 Q3 | 417.5 Million INR | 2.35% |
| 2019 Q2 | 407.91 Million INR | 13.87% |
| 2019 Q4 | 333.77 Million INR | -20.05% |
| 2019 Q1 | 358.24 Million INR | 90.94% |
| 2019 FY | 1.54 Billion INR | 23.57% |
| 2018 Q1 | 324.42 Million INR | 0.0% |
| 2018 FY | 1.24 Billion INR | -19.63% |
| 2018 Q4 | 187.62 Million INR | -42.48% |
| 2018 Q3 | 326.16 Million INR | -20.77% |
| 2018 Q2 | 411.65 Million INR | 26.89% |
| 2017 FY | 1.55 Billion INR | -2.69% |
| 2016 FY | 1.59 Billion INR | -4.96% |
| 2016 Q4 | 375.78 Million INR | 0.0% |
| 2015 FY | 1.68 Billion INR | -9.78% |
| 2014 FY | 1.86 Billion INR | -18.38% |
| 2013 Q1 | 516.75 Million INR | -1.62% |
| 2013 Q3 | 617.73 Million INR | 0.0% |
| 2013 Q4 | 617.4 Million INR | -0.05% |
| 2013 FY | 2.28 Billion INR | 14.9% |
| 2012 Q1 | 497.72 Million INR | 0.0% |
| 2012 FY | 1.98 Billion INR | 12.29% |
| 2012 Q2 | 483.83 Million INR | -2.79% |
| 2012 Q3 | 480.34 Million INR | -0.72% |
| 2012 Q4 | 525.25 Million INR | 9.35% |
| 2011 FY | 1.76 Billion INR | 9.51% |
| 2010 FY | 1.61 Billion INR | 32.37% |
| 2009 FY | 1.22 Billion INR | 21.47% |
| 2008 FY | 1 Billion INR | 25.08% |
| 2007 FY | 803.46 Million INR | 51.01% |
| 2006 FY | 532.06 Million INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alkem Laboratories Limited | 52.29 Billion INR | 95.827% |
| Amrutanjan Health Care Limited | 1.55 Billion INR | -40.221% |
| Alembic Pharmaceuticals Limited | 26.78 Billion INR | 91.85% |
| AstraZeneca Pharma India Limited | 6.22 Billion INR | 64.925% |
| Aurobindo Pharma Limited | 154.68 Billion INR | 98.589% |
| Biofil Chemicals and Pharmaceuticals Limited | 14.57 Million INR | -14870.027% |
| Eris Lifesciences Limited | 10.42 Billion INR | 79.068% |
| FDC Limited | 8.33 Billion INR | 73.813% |
| Glenmark Life Sciences Limited | 12.43 Billion INR | 82.445% |
| Ipca Laboratories Limited | 29.8 Billion INR | 92.678% |
| Jagsonpal Pharmaceuticals Limited | 652.59 Million INR | -234.45% |
| Krebs Biochemicals & Industries Limited | 192.72 Million INR | -1032.475% |
| Laurus Labs Limited | 24.62 Billion INR | 91.135% |
| Lupin Limited | 123.71 Billion INR | 98.236% |
| Medicamen Biotech Limited | 495.49 Million INR | -340.486% |
| Medico Remedies Limited | 262.14 Million INR | -732.59% |
| Megasoft Limited | 342.07 Million INR | -538.05% |
| NATCO Pharma Limited | 25.73 Billion INR | 91.519% |
| Piramal Pharma Limited | 24.47 Billion INR | 91.081% |
| Sigachi Industries Limited | 2 Billion INR | -9.005% |
| Solara Active Pharma Sciences Limited | 861.2 Million INR | -153.435% |
| Sun Pharmaceutical Industries Limited | 258.48 Billion INR | 99.156% |
| Suven Pharmaceuticals Limited | 4.12 Billion INR | 47.067% |
| Syncom Formulations (India) Limited | 942.39 Million INR | -131.599% |
| Themis Medicare Limited | 1.5 Billion INR | -45.128% |
| Torrent Pharmaceuticals Limited | 46.75 Billion INR | 95.332% |
| Valiant Laboratories Limited | -60.66 Million INR | 3697.826% |
| Wanbury Limited | 1.73 Billion INR | -26.114% |
| Windlas Biotech Limited | 1.33 Billion INR | -63.025% |
| ZIM Laboratories Limited | 1.26 Billion INR | -72.279% |
| Zydus Lifesciences Limited | 125.21 Billion INR | 98.257% |
| Ajanta Pharma Limited | 21.06 Billion INR | 89.638% |
| Ind-Swift Laboratories Limited | 6.19 Billion INR | 64.765% |
| Achyut Healthcare Limited | 4.86 Million INR | -44799.918% |
| Lasa Supergenerics Limited | 121.02 Million INR | -1703.342% |
| Sun Pharma Advanced Research Company Limited | -602.4 Million INR | 462.311% |
| Aarti Pharmalabs Limited | 5.83 Billion INR | 62.572% |
| Alpa Laboratories Limited | 188.89 Million INR | -1055.449% |
| Gufic Biosciences Limited | 4.16 Billion INR | 47.631% |
| Ind-Swift Limited | 2.17 Billion INR | -0.463% |
| Indoco Remedies Limited | 6.04 Billion INR | 63.872% |
| Hester Biosciences Limited | 1.27 Billion INR | -71.365% |
| Bliss GVS Pharma Limited | 3.69 Billion INR | 40.938% |
| Bajaj HealthCare Limited | 1.47 Billion INR | -48.293% |
| RPG Life Sciences Limited | 2.48 Billion INR | 12.099% |
| Mankind Pharma Limited | 44.52 Billion INR | 95.098% |
| Glenmark Pharmaceuticals Limited | 69.34 Billion INR | 96.852% |
| Unichem Laboratories Limited | 4.86 Billion INR | 55.136% |
| Bal Pharma Limited | 770.19 Million INR | -183.381% |
| Strides Pharma Science Limited | 14.38 Billion INR | 84.831% |
| Jubilant Pharmova Limited | 19.64 Billion INR | 88.889% |
| Dr. Reddy's Laboratories Limited | 163.6 Billion INR | 98.666% |
| Divi's Laboratories Limited | 32.44 Billion INR | 93.272% |
| Nectar Lifesciences Limited | 2.97 Billion INR | 26.563% |
| Shilpa Medicare Limited | 3.54 Billion INR | 38.464% |
| Aarti Drugs Limited | 8.31 Billion INR | 73.755% |
| IOL Chemicals and Pharmaceuticals Limited | 4.58 Billion INR | 52.354% |
| Suven Life Sciences Limited | -200.79 Million INR | 1186.961% |
| J. B. Chemicals & Pharmaceuticals Limited | 22.69 Billion INR | 90.385% |
| Hikal Limited | 3.14 Billion INR | 30.559% |
| Procter & Gamble Health Limited | 5.78 Billion INR | 62.248% |
| Sequent Scientific Limited | 2.97 Billion INR | 26.728% |
| Novartis India Limited | 1.32 Billion INR | -64.488% |
| Granules India Limited | 16.79 Billion INR | 87.008% |
| Wockhardt Limited | 16.24 Billion INR | 86.56% |
| Brooks Laboratories Limited | 65.62 Million INR | -3226.097% |
| Neuland Laboratories Limited | 8.24 Billion INR | 73.537% |
| Morepen Laboratories Limited | 6.16 Billion INR | 64.576% |
| Kilitch Drugs (India) Limited | 620.47 Million INR | -251.759% |
| Mangalam Drugs & Organics Limited | 703.6 Million INR | -210.2% |